Angiotensin-Converting Enzyme (ACE) Inhibitors
Learn MoreSGLT-2 inhibitors are a breakthrough class of medications that are used to treat type 2 diabetes by targeting a specific protein in the kidneys These inhibitors work by blocking the reabsorption of glucose allowing excess glucose to be excreted in the urine By reducing blood glucose levels SGLT-2 inhibitors help to improve glycemic control and lower the risk of cardiovascular events Additionally these medications have been shown to promote weight loss and reduce blood pressure With their unique mechanism of action and multiple benefits SGLT-2 inhibitors have become an important tool in the management of type 2 diabetes
Catalog Number | Chemical Name | CAS # | Price |
---|---|---|---|
EI-0374 | Bexgliflozin (EGT1442) | 1118567-05-7 | Online Inquiry |
EI-0503 | Canagliflogin | 842133-18-0 | Online Inquiry |
EI-0709 | Dapagliflozin | 461432-26-8 | Online Inquiry |
EI-0806 | Empagliflozin | 864070-44-0 | Online Inquiry |
EI-0832 | Ertugliflozin | 1210344-57-2 | Online Inquiry |
EI-1225 | Ipragliflozin | 761423-87-4 | Online Inquiry |
EI-1377 | LX-4211 | 1018899-04-1 | Online Inquiry |
EI-1866 | Remogliflozin | 329045-45-6 | Online Inquiry |
EI-2187 | Tofogliflozin | 903565-83-3 | Online Inquiry |
SGLT-2 inhibitors are a widely used class of medications that have diverse applications in the field of medicine One of their primary applications is in the management of type 2 diabetes By inhibiting the SGLT-2 transporter in the kidneys these inhibitors prevent the reabsorption of glucose leading to an increase in urinary glucose excretion and a reduction in blood glucose levels This mechanism helps to control blood sugar levels and improve glycemic control in patients with diabetes
Beyond their role in diabetes management SGLT-2 inhibitors have also shown promising results in the treatment of heart failure These medications have been found to reduce the risk of cardiovascular events and hospitalizations for heart failure in patients with or without diabetes By improving cardiac function and reducing fluid overload SGLT-2 inhibitors provide an additional therapeutic option for individuals with heart failure
Furthermore SGLT-2 inhibitors have been investigated for their potential benefits in chronic kidney disease These medications have shown renoprotective effects including a reduction in albuminuria and a slower decline in estimated glomerular filtration rate (eGFR) This makes them a valuable tool in managing kidney complications associated with diabetes and other conditions
In summary SGLT-2 inhibitors have a wide range of applications in the field of medicine including the management of type 2 diabetes treatment of heart failure and potential benefits in chronic kidney disease These medications offer effective and innovative therapeutic options for patients with these conditions
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.